|
1）Kojima S, Hibi S, Kosaka Y, et al. Immuno-suppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000; 96: 2049-54
|
|
|
|
2）Bacigalupo A, Bruno B, Saracco P, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. Euro-pean Group for Blood and Marrow Transplan-tation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood. 2000; 95: 1931-4
|
|
|
|
|
|
3）Tsuge I, Kojima S. Comparison of antibody specificities of 4 anti-thymocyte antilymphocyte globulin products. Current therapeutic research-clinical and experimental. 1995; 56: 671-7
|
|
|
|
|
|
4）Solomou EE, Rezvani K, Mielke S, et al. Deficient CD4＋ CD25＋ FOXP3＋ T regulatory cells in acquired aplastic anemia. Blood. 2007; 110: 1603-6
|
|
|
|
|
5）Feng X, Kajigaya S, Solomou EE, et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4＋CD25highFOXP3＋ regulatory T cells in vitro. Blood. 2008; 111: 3675-83
|
|
|
|
|
|
6）Garg R, Faderl S, Garcia-Manero G, et al. Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Leukemia. 2009; 23: 1297-302
|
|
|
|
|
|
7）Vallejo C, Montesinos P, Rosell A, et al. Comparison between lymphoglobulin- and thymoglobulin-based immunosupressive therapy as first-line treatment for patients with aplastic anemia. Blood. 2009; 114: 1237-8
|
|
|
|
|
|
8）Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011; 365: 430-8
|
|
|
|
|
|
9）Marsh JC, Bacigalupo A, Schrezenmeier H, et al. Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. Blood. 2012; 119: 5391-6
|
|
|
|
|
|
10）Atta EH, Dias DS, Marra VL, et al. Comparison between horse and rabbit antithymocyte globulin as first-line treatment for patients with severe aplastic anemia: a single-center retrospective study. Ann Hematol. 2010; 89: 851-9
|
|
|
|
|
|
11）Afable MG, Shaik M, Sugimoto Y, et al. Efficacy of rabbit antithymocyte globulin in severe aplastic anemia. Haematologica.2011; 23: 1269-75
|
|
|
|
|
|
12）Chen C, Xue HM, Xu HG, et al. Rabbit-antithymocyte globulin combined with cyclosporin A as a first-line therapy: improved, effective, and safe for children with acquired severe aplastic anemia. J Cancer Res Clini Oncol. 2012; 138: 1105-11
|
|
|
|
|
|
13）Takahashi Y, Muramatsu H, Sakata N, et al. Rabbit antithymocyte globulin and cyclosporine as first-line therapy for children with acuired aplastic anemia. Blood.; in press
|
|
|
|
|
|
14）Scheinberg P, Fischer SH, Li L, et al. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood. 2007; 109: 3219-24
|
|
|
|
|
|
15）Ohata K, Iwaki N, Kotani T, et al. An Epstein-Barr virus-associated leukemic lymphoma in a patient treated with rabbit antithymocyte globulin and cyclosporine for hepatitis-associated aplastic anemia. Acta Haematol. 2012; 127: 96-9
|
|
|
|
|
|
16）谷ヶ崎博，工藤寿子，小島勢二．再生不良性貧血に対する免疫抑制療法後に合併したEBウイルスリンパ増殖症(EBV-LPD). 日小児会誌．2005; 109(2): 162
|
|
|
|
|
|
17）Minauchi K, Shima K, Hirano R, et al. Early development of EBV-LPD in a patient with SAA treated with rabbit ATG as initial therapy. 臨床血液．2011; 52(9): 1234
|
|
|
|
|
|
18）Tahara K, Hoshino T, Hatsumi N, et al. 再生不良性貧血に対する免疫抑制療法後のEpstein-Barrウイルス関連LPD 1症例報告．臨床血液．2010; 51(9): 1120
|
|
|
|
|
|
19）白崎良輔，田代晴子，山本 義，他．ATG療法後にEBV関連リンパ増殖性疾患を発症した再生不良性貧血の1例．臨床血液．2011; 52(8): 728
|
|
|
|
|
|
20）谷村美紀，細井裕樹，花岡伸佳，他．免疫抑制療法後に急速に進行するEBV-LPDを発症した再生不良性貧血の1例．和歌山医学．2011; 62(4): 146
|
|
|
|
|
|
21）住 昌彦，清水郁夫，佐藤慶二郎，他．ATG投与後EBV関連リンパ腫増殖性疾患を合併したT細胞性顆粒リンパ球増多症合併重症再生不良性貧血．臨床血液．2011; 52(3): 157
|
|
|
|
|
|
22）Watanabe J, Sato K, Katsurada Y, et al. EBV-associated DLBCL after immunosuppressive therapy with rabbit ATG for aplastic anemia. 臨床血液．2011; 52(9): 1195
|
|
|
|
|
|
23）Kimura K, Kiguchi T, Masunari T, et al. EBV-associated LPD complicated after ATG therapy in a patient with severe aplastic anemia. 臨床血液．2012; 53(9): 1309
|
|
|
|
|